Roche gets CE mark for 'Accu Chek Solo' insulin micropump

The Swiss drugmaker said it would start the pilot commercialisation phase for the insulin delivery system in Austria, Poland, Switzerland and the UK in the coming weeks, and was conducting a clinical study in several European countries.

“This important milestone will enable us to further expand access to insulin pump therapy to those people with diabetes who can benefit most from this therapy option - so they can spend more time in their ideal target range and experience an improved quality of life," said Roche Diagnostics chief executive officer Roland Diggelmann.

“The new modular design of our Accu-Chek Solo micropump system responds to the needs of people with diabetes for more discretion and flexibility.”

Roche said the Accu-Chek Solo micropump system allowed for “convenience and personalisation” in insulin pump therapy, while contributing to a more targeted and effective diabetes management.

It offered the functionalities of a traditional insulin pump, as well as the “technological advancement” of tube-free insulin delivery, the company explained.

The system consists of two parts - a small, lightweight and semi-disposable insulin micropump and a fully-featured remote control incorporating blood glucose monitoring and bolus advice.

Roche said the system provides bolus insulin dosing both from the remote control or directly from the pump, as well as the option to detach and re-attach the pump without wasting insulin.

In addition, the system connects to Roche Diabetes Care's digital products such as the Accu-Chek Smart Pix system, which reportedly provides decision and therapy support at the doctor's office with a tool for efficient, effective and personalised diabetes management.